Today: 18 January 2026
Subscribe
Browse Category

Mergers & Acquisitions News 20 December 2025 - 21 December 2025

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Dateline: December 21, 2025 (Week Ahead: Dec. 22–26, 2025) Warner Bros. Discovery, Inc. Series A stock (NASDAQ: WBD) heads into a holiday-shortened week with the kind of headline-driven volatility that rarely shows up in “normal” media earnings models. The reason is simple: WBD is now trading less like a traditional entertainment company and more like a live deal—anchored between two…
21 December 2025
····
Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce, Inc. (NYSE: CRM) heads into the Christmas holiday week with a busy backdrop for investors: fresh product distribution news for its Agentforce platform, a newly announced acquisition aimed at “agentic” marketing, and a market calendar that’s likely to amplify day-to-day volatility simply because liquidity is thinner than usual. As of Sunday, December 21, 2025, the latest available trade data…
21 December 2025
···
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in…
21 December 2025
····
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC With…
21 December 2025
····
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition…
21 December 2025
···
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters On December 19, FOLD shares surged…
20 December 2025
····
ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow, Inc. (NYSE: NOW) heads into the weekend with investors still digesting one of the most turbulent stretches the enterprise software leader has seen this year: a fresh stock split, a confirmed AI acquisition closing, and intense market debate over whether a rumored $7 billion cybersecurity deal would be a smart strategic leap—or an expensive distraction. As of Saturday, Dec.…
20 December 2025
····
Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

December 20, 2025 — Newly surfaced U.S. regulatory filings are putting sharper names and structures behind a $200 million divestment at the center of Tether’s expanding push from crypto into AI infrastructure. Peak Mining—the bitcoin-mining business that German AI and data center operator Northern Data agreed to sell—has been acquired by three entities listed in filings as Highland Group Mining…
20 December 2025
····
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in…
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh…
20 December 2025
···
DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

Dec. 20, 2025 — Trump Media & Technology Group Corp. (NASDAQ: DJT) is back in the spotlight after announcing a surprise all-stock merger with nuclear fusion company TAE Technologies—a deal the companies describe as valued at more than $6 billion and aimed at accelerating the buildout of a utility-scale fusion power plant. GlobeNewswire The announcement sparked a sharp rally in…
20 December 2025
···
Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media & Technology Group Corp. (NASDAQ: DJT) is ending the week the way it often lives: loudly, unpredictably, and with traders glued to their screens. After announcing a surprise plan to merge with nuclear fusion developer TAE Technologies in a deal valued at more than $6 billion, DJT shares ripped higher on massive volume—turning a social-media stock into (at…
20 December 2025
····
1 … 4 5 6 7 8 … 34

Stock Market Today

  • Nvidia stock muted after China blocks H200 shipments; traders eye earnings and AI-chip roadmap
    January 18, 2026, 1:53 PM EST. NVIDIA shares closed down 0.41% to $186.23 on Friday after a Financial Times report that Chinese customs blocked shipments of the H200 AI processor. Suppliers paused output as the halt looms over Nvidia's supply chain. With markets closed for MLK Day, focus shifts to Tuesday's session and Nvidia's Feb. 25 results. Analysts at Wolfe Research keep Nvidia on the Alpha List, citing a ramp for Blackwell and Rubin chips; they see upside to 2026 revenue if the trend holds. Options activity could amplify moves ahead of expiration. A pause that drags into a formal ban would delay shipments; a temporary pause could ease near-term pressure. The broader semis index rose, but the China hinge remains.
Go toTop